Does FACEFORMER® Therapy have an impact on diabetes?

Thus, the question arises, could FACEFORMER therapy be a complementary therapeutical option for the treatment of a diabetes patient, support or even replace a drug therapy with antidiabetics? This observed positive effect of the FACEFORMER on the sugar metabolism could be hypothetically explained as follows: The FACEFORMER therapy has a stimulating effect on the inner pharyngeal musculature and the corresponding nerve structures. An activation of the vagus nerve occurs, which has an activating effect on the gastrointestinal musculature and its mucous membranes.

According to latest knowledge, the secretion of Incretin in the small intestine mucous membrane has a distinct impact on the glucose metabolism. Incretins, which are reactively released after a meal in the small intestine, have an anti-diabetic effect. According to this principle of action, the gliptins, DPP4 inhibitors, are successfully applied nowadays.

The incretins have a stimulating effect on the beta cells of the pancreas, resulting in an increased release of insulin and consequently a reduction in blood glucose. In addition, an effect of incretins on the alpha cells of the pancreas has been demonstrated, resulting in a reduction of gluconeogenesis with a decrease in glucose formation. Furthermore, an improvement of the diabetic metabolic situation is given by an increased uptake of glucose into the cell and its metabolism.